Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
Latest Information Update: 18 Apr 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Tivumecirnon (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Hodgkin's disease; Lymphoma; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms KEYNOTE-877
- Sponsors RAPT Therapeutics
- 10 Apr 2024 Results of phase 2 cohort of HNSCC, presented at the 115th Annual Meeting of the American Association for Cancer Research
- 09 Apr 2024 According to a RAPT Therapeutics media release, company today announced safety and efficacy data from its ongoing Phase 2 trial and presented this data at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.The AACR poster highlighted data from the 32-patient CPI-experienced HNSCC cohort in the trial evaluating tivumecirnon, an oral small molecule CCR4 antagonist designed to block the migration of regulatory T cells, in combination with pembrolizumab.
- 09 Apr 2024 Results published in a RAPT Therapeutics media release